There is a growing interest in continuous biopharmaceutical processing due to the advantages of small footprint, increased productivity, consistent product quality, high process flexibility and robustness, facility cost-effectiveness, and reduced capital and operating cost. To support the decision making of biopharmaceutical manufacturing, comparisons between conventional batch and continuous processing are provided.
Various process unit operations in different operating modes are summarized. Software implementation as well as computational methods used are analyzed pointing to the advantages and disadvantages that have been highlighted in the literature. Economic analysis methods and their applications in different parts of the processes are also discussed with examples from publications in the last decade.
The results of the comparison between batch and continuous process operation alternatives are discussed. Possible improvements in process design and analysis are recommended. The methods used here do not reflect Lilly’s cost structures or economic evaluation methods.
This paper provides a review of the work that has been published in the literature on computational process design and economic analysis methods on continuous biopharmaceutical antibody production and its comparison with a conventional batch process.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Newswire PR. Monoclonal antibodies (mAbs) market analysis by source (chimeric, murine, humanized, human), by type of production, by indication (cancer, autoimmune, inflammatory, infectious, microbial, viral diseases), by end-use and segment forecasts, 2013–2024. LON-Reportbuyer: Y; 2017.
Gjoka X, Gantier R, Schofield M. Transfer of a three step mAb chromatography process from batch to continuous: optimizing productivity to minimize consumable requirements. J Biotechnol. 2017;242:11–8. https://doi.org/10.1016/j.jbiotec.2016.12.005.
Gjoka X, Rogler K, Martino RA, Gantier R, Schofield M. A straightforward methodology for designing continuous monoclonal antibody capture multi-column chromatography processes. J Chromatogr A. 2015;1416:38–46. https://doi.org/10.1016/j.chroma.2015.09.005.
Ng CKS, Rousset F, Valery E, Bracewell DG, Sorensen E. Design of high productivity sequential multi-column chromatography for antibody capture. Food Bioprod Process. 2014;92(C2):233–41. https://doi.org/10.1016/j.fbp.2013.10.003.
America PRaMo. Medicines in development: biologics 2013 report. Pharmaceutical Research and Manufacturers of America. 2013. http://phrma-docs.phrma.org/sites/default/files/pdf/biologics2013.pdf. Accessed 01 June 2018.
Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. Mabs-Austin. 2015;7(1):9–14. https://doi.org/10.4161/19420862.2015.989042.
Newswire PR. Monoclonal antibodies (mAbs) market Size worth $138.6 billion by 2024: grand view research, Inc. bc-Grand-View-Research: Y; 2016.
Gronemeyer P, Ditz R, Strube J. Trends in upstream and downstream process development for antibody manufacturing. Bioengineering. 2014;1(4):188–212. https://doi.org/10.3390/bioengineering1040188.
Zydney AL. Continuous downstream processing for high value biological products: a review. Biotechnol Bioeng. 2016;113(3):465–75.
Whitford WG. Single-use systems support continuous bioprocessing by perfusion culture. In: Subramanian G, editor. Continuous processing in pharmaceutical manufacturing. 2014, .
Godawat R, Konstantinov K, Rohani M, Warikoo V. End-to-end integrated fully continuous production of recombinant monoclonal antibodies. J Biotechnol. 2015;213:13–9. https://doi.org/10.1016/j.jbiotec.2015.06.393.
Taracena FL. An economic analysis for product and process design. Qual Eng. 2006;18(1):33–7. https://doi.org/10.1080/08982110500403474.
Farid SS. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848(1):8–18. https://doi.org/10.1016/j.jchromb.2006.07.037.
Farid SS, Pollock J, Ho SV. Evaluating the economic and operational feasibility of continuous processes for monoclonal antibodies. Continuous Processing in Pharmaceutical Manufacturing. Wiley-VCH Verlag GmbH & Co. KGaA; 2014;433–56. https://doi.org/10.1002/9783527673681.ch17.
Torres-Acosta MA, Ruiz-Ruiz F, Benavides J, Rito-Palomares M. Process economics: evaluation of the potential of ATPS as a feasible alternative to traditional fractionation techniques. Food Eng Ser. 2017;1:161–78. https://doi.org/10.1007/978-3-319-59309-8_9.
Xu S, Gavin J, Jiang R, Chen H. Bioreactor productivity and media cost comparison for different intensified cell culture processes. Biotechnol Prog. 2016;33:867–78. https://doi.org/10.1002/btpr.2415.
Pollock J, Coffman J, Ho SV, Farid SS. Integrated continuous bioprocessing: economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. Biotechnol Prog. 2017;33:854–66. https://doi.org/10.1002/btpr.2492.
Hammerschmidt N, Tscheliessnig A, Sommer R, Helk B, Jungbauer A. Economics of recombinant antibody production processes at various scales: industry-standard compared to continuous precipitation. Biotechnol J. 2014;9(6):766–75. https://doi.org/10.1002/biot.201300480.
Walther J, Godawat R, Hwang C, Abe Y, Sinclair A, Konstantinov K. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production. J Biotechnol. 2015;213:3–12. https://doi.org/10.1016/j.jbiotec.2015.05.010.
Bunnak P, Allmendinger R, Ramasamy SV, Lettieri P, Titchener-Hooker NJ. Life-cycle and cost of goods assessment of fed-batch and perfusion-based manufacturing processes for mAbs. Biotechnol Prog. 2016;32(5):1324–35. https://doi.org/10.1002/btpr.2323.
Pollock J, Ho SV, Farid SS. Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty. Biotechnol Bioeng. 2013;110(1):206–19. https://doi.org/10.1002/bit.24608.
Petrides D. Bioprocess design and economics. In: Roger G. Harrison PWT, Scott R. Rudge and Demetri P. Petrides, editor. Bioseparations Science and Engineering 2ed., 2015.
Chatterjee S, editor. FDA perspective on continuous manufacturing. IFPAC Annual Meeting; 2012; Baltimore: FDA U.S. Food and Drug Administration Protecting and Promoting Public Health.
Jain E, Kumar A. Upstream processes in antibody production: evaluation of critical parameters. Biotechnol Adv. 2008;26(1):46–72. https://doi.org/10.1016/j.biotechadv.2007.09.004.
Novais JL, Titchener-Hooker NJ, Hoare M. Economic comparison between conventional and disposables-based technology for the production of biopharmaceuticals. Biotechnol Bioeng. 2001;75(2):143–53.
Hutterer KM, Hong RW, Lull J, Zhao X, Wang T, Pei R, et al. Monoclonal antibody disulfide reduction during manufacturing: untangling process effects from product effects. Mabs-Austin. 2013;5(4):608–13. https://doi.org/10.4161/mabs.24725.
Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. Mabs-Austin. 2010;2(5):480–99.
Jungbauer A. Continuous downstream processing of biopharmaceuticals. Trends Biotechnol. 2013;31(8):479–92. https://doi.org/10.1016/j.tibtech.2013.05.011.
Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. Mabs-Austin. 2009;1(5):443–52.
Yang WC, Minkler DF, Kshirsagar R, Ryll T, Huang Y-M. Concentrated fed-batch cell culture increases manufacturing capacity without additional volumetric capacity. J Biotechnol. 2016;217:1–11. https://doi.org/10.1016/j.jbiotec.2015.10.009.
Patil R, Walther J. Continuous manufacturing of recombinant therapeutic proteins: upstream and downstream technologies. Adv Biochem Eng Biotechnol. 2017. https://doi.org/10.1007/10_2016_58.
Arunkumar A, Singh N, Peck M, Borys MC, Li ZJ. Investigation of single-pass tangential flow filtration (SPTFF) as an inline concentration step for cell culture harvest. J Membrane Sci. 2017;524:20–32. https://doi.org/10.1016/j.memsci.2016.11.007.
Clincke MF, Molleryd C, Zhang Y, Lindskog E, Walsh K, Chotteau V. Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor. Part I. effect of the cell density on the process. Biotechnol Prog. 2013;29(3):754–67. https://doi.org/10.1002/btpr.1704.
Bielser JM, Wolf M, Souquet J, Broly H, Morbidelli M. Perfusion mammalian cell culture for recombinant protein manufacturing—a critical review. Biotechnol Adv. 2018;36(4):1328–40. https://doi.org/10.1016/j.biotechadv.2018.04.011.
Xenopoulos A. A new, integrated, continuous purification process template for monoclonal antibodies: process modeling and cost of goods studies. J Biotechnol. 2015;213:42–53. https://doi.org/10.1016/j.jbiotec.2015.04.020.
Eggersgluess JK, Richter M, Dieterle M, Strube J. Multi-stage aqueous two-phase extraction for the purification of monoclonal antibodies. Chem Eng Technol. 2014;37(4):675–82. https://doi.org/10.1002/ceat.201300604.
Schmidt A, Richter M, Rudolph F, Strube J. Integration of aqueous two-phase extraction as cell harvest and capture operation in the manufacturing process of monoclonal antibodies. Antibodies. 2017;6(4):21. https://doi.org/10.3390/antib6040021.
Gonzalez-Valdez J, Mayolo-Deloisa K, Rito-Palomares M. Novel aspects and future trends in the use of aqueous two-phase systems as a bioengineering tool. J Chem Technol Biot. 2018;93(7):1836–44. https://doi.org/10.1002/jctb.5434.
Torres-Acosta MA, Mayolo-Deloisa K, González-Valdez J, Rito-Palomares M. Aqueous two-phase systems at large scale: challenges and opportunities. Biotechnol J. 0(0):1800117. https://doi.org/10.1002/biot.201800117.
Godawat R, Brower K, Jain S, Konstantinov K, Riske F, Warikoo V. Periodic counter-current chromatography—design and operational considerations for integrated and continuous purification of proteins. Biotechnol J. 2012;7(12):1496–508. https://doi.org/10.1002/biot.201200068.
Dutta AK, Tan J, Napadensky B, Zydney AL, Shinkazh O. Performance optimization of continuous countercurrent tangential chromatography for antibody capture. Biotechnol Prog. 2016;32(2):430–9. https://doi.org/10.1002/btpr.2250.
Napadensky B, Shinkazh O, Teella A, Zydney AL. Continuous countercurrent tangential chromatography for monoclonal antibody purification. Sep Sci Technol. 2013;48(9):1289–97. https://doi.org/10.1080/01496395.2013.767837.
Shinkazh O, inventor Countercurrent tangential chromatography methods, systems, and apparatus. US2011.
Shinkazh O, Kanani D, Barth M, Long M, Hussain D, Zydney AL. Countercurrent tangential chromatography for large-scale protein purification. Biotechnol Bioeng. 2011;108(3):582–91. https://doi.org/10.1002/bit.22960.
Espitia-Saloma E, Vazquez-Villegas P, Aguilar O, Rito-Palomares M. Continuous aqueous two-phase systems devices for the recovery of biological products. Food Bioprod Process. 2014;92(C2):101–12. https://doi.org/10.1016/j.fbp.2013.05.006.
Rosa PAJ, Azevedo AM, Sommerfeld S, Bäcker W, Aires-Barros MR. Continuous aqueous two-phase extraction of human antibodies using a packed column. J Chromatogr B. 2012;880(Supplement C):148–56. https://doi.org/10.1016/j.jchromb.2011.11.034.
Ransohoff TC. Bisschops MAT. Google Patents: Continuous processing methods for biological products; 2013.
Coffman J, Goby J, Godfrey S, Orozco R, Vogel JH. Methods, apparatuses, and systems for continuously inactivating a virus during manufacture of a biological product. Google Patents; 2017.
Klutz S, Lobedann M, Bramsiepe C, Schembecker G. Continuous viral inactivation at low pH value in antibody manufacturing. Chem Eng Process: Process Intensif. 2016;102(Supplement C):88–101. https://doi.org/10.1016/j.cep.2016.01.002.
Orozco R, Godfrey S, Coffman J, Amarikwa L, Parker S, Hernandez L, et al. Design, construction, and optimization of a novel, modular, and scalable incubation chamber for continuous viral inactivation. Biotechnol Prog. 2017;33(4):954–65. https://doi.org/10.1002/btpr.2442.
Steinebach F, Muller-Spath T, Morbidelli M. Continuous counter-current chromatography for capture and polishing steps in biopharmaceutical production. Biotechnol J. 2016;11(9):1126–41. https://doi.org/10.1002/biot.201500354.
Rucker-Pezzini J, Arnold L, Hill-Byrne K, Sharp T, Avazhanskiy M, Forespring C. Single pass diafiltration integrated into a fully continuous mAb purification process. Biotechnol Bioeng. 2018;115(8):1949–57. https://doi.org/10.1002/bit.26708.
Nambiar AMK, Li Y, Zydney AL. Countercurrent staged diafiltration for formulation of high value proteins. Biotechnol Bioeng. 2018;115(1):139–44. https://doi.org/10.1002/bit.26441.
Kateja N, Kumar D, Sethi S, Rathore AS. Non-protein A purification platform for continuous processing of monoclonal antibody therapeutics. J Chromatogr A. 2018;1579:60–72. https://doi.org/10.1016/j.chroma.2018.10.031.
Somasundaram B, Pleitt K, Shave E, Baker K, Lua LHL. Progression of continuous downstream processing of monoclonal antibodies: current trends and challenges. Biotechnol Bioeng. 2018;115:2893–907. https://doi.org/10.1002/bit.26812.
Rathore AS, Kateja N, Kumar D. Process integration and control in continuous bioprocessing. Curr Opin Chem Eng. 2018;22:18–25.
Flickinger MC. Upstream industrial biotechnology. John Wiley & Sons.
Castilho LR. Continuous animal cell perfusion processes: the first step toward integrated continuous biomanufacturing. In: Subramanian G, editor. Continuous Processing in Pharmaceutical Manufacturing 2015.
Lee R, Mikol V, Allen E, Ruetsch N, Cameron B, Oligino T et al. Humanized anti-CXCR5 antibodies, derivatives thereof and their use. Google Patents; 2011.
Jozala AF, Geraldes DC, Tundisi LL, Feitosa VD, Breyer CA, Cardoso SL, et al. Biopharmaceuticals from microorganisms: from production to purification. Braz J Microbiol. 2016;47:51–63. https://doi.org/10.1016/j.bjm.2016.10.007.
Pollock J, Bolton G, Coffman J, Ho SV, Bracewell DG, Farid SS. Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. J Chromatogr A. 2013;1284:17–27. https://doi.org/10.1016/j.chroma.2013.01.082.
Liu S, Simaria AS, Farid SS, Papageorgiou LG. Designing cost-effective biopharmaceutical facilities using mixed-integer optimization. Biotechnol Prog. 2013;29(6):1472–83. https://doi.org/10.1002/btpr.1795.
Li YF, Venkatasubramanian V. Integrating design of experiments and principal component analysis to reduce downstream cost of goods in monoclonal antibody production. J Pharm Innov. 2016;11(4):352–61. https://doi.org/10.1007/s12247-016-9263-8.
Klutz S, Holtmann L, Lobedann M, Schembecker G. Cost evaluation of antibody production processes in different operation modes. Chem Eng Sci. 2016;141:63–74. https://doi.org/10.1016/j.ces.2015.10.029.
Torres-Acosta MA, Aguilar-Yanez JM, Rito-Palomares M, Titchener-Hooker NJ. Economic analysis of uricase production under uncertainty: contrast of chromatographic purification and aqueous two-phase extraction (with and without PEG recycle). Biotechnol Prog. 2016;32(1):126–33. https://doi.org/10.1002/btpr.2200.
Liu S, Farid SS, Papageorgiou LG. Integrated optimization of upstream and downstream processing in biopharmaceutical manufacturing under uncertainty: a chance constrained programming approach. Ind Eng Chem Res. 2016;55(16):4599–612. https://doi.org/10.1021/acs.iecr.5b04403.
Arnold L, Lee K, Rucker-Pezzini J, Lee JH. Implementation of fully integrated continuous antibody processing: effects on productivity and COGm. Biotechnol J. 2018. https://doi.org/10.1002/biot.201800061.
Hummel J, Pagkaliwangan M, Gjoka X, Davidovits T, Stock R, Ransohoff T, et al. Modeling the downstream processing of monoclonal antibodies reveals cost advantages for continuous methods for a broad range of manufacturing scales. Biotechnol J. 2018. https://doi.org/10.1002/biot.201700665.
Grilo AL, Mateus M, Aires-Barros MR, Azevedo AM. Monoclonal antibodies production platforms: an opportunity study of a non-protein-A chromatographic platform based on process economics. Biotechnol J. 2017;12(12). https://doi.org/10.1002/biot.201700260.
The biopharmaceutical industry’s leading process analysis and economic modelling package. In: BioSolve Process 7. Biopharm. 2016. https://biopharmservices.com/wp-content/uploads/2016/02/Process-2pp-A4-2016-2-FINAL.pdf. Accessed 8/9 2017.
Aspentech. Aspen Batch Process Developer https://www.aspentech.com/en/products/pages/aspen-batch-process-developer. Accessed 12/19 2018.
Aspentech. Aspen Chromatogrpahy. https://www.aspentech.com/en/products/pages/aspen-chromatography. Accessed 12/19 2018.
Ashouri P. A dynamic simulation framework for biopharmaceutical capacity management: University College London; 2011.
Sachidananda M, Erkoyuncu J, Steenstra D, Michalska S. Discrete event simulation modelling for dynamic decision making in biopharmaceutical manufacturing. Procedia CIRP. 2016;49:39–44. https://doi.org/10.1016/j.procir.2015.07.026.
Towler G, Sinnott RK. Chemical engineering design: principles, practice and economics of plant and process design: Elsevier; 2012.
Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S, et al. Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care. 2018;24(2):109–+.
Pannell DJ. Sensitivity analysis: strategies, methods, concepts, examples. Agric Econ. 1997;16:139–52.
Torres-Acosta MA, Aguilar-Yanez JM, Rito-Palomares M, Titchener-Hooker NJ. Economic analysis of Royalactin production under uncertainty: evaluating the effect of parameter optimization. Biotechnol Prog. 2015;31(3):744–9. https://doi.org/10.1002/btpr.2073.
Vermasvuori R, Hurme M. Economic comparison of diagnostic antibody production in perfusion stirred tank and in hollow fiber bioreactor processes. Biotechnol Prog. 2011;27(6):1588–98. https://doi.org/10.1002/btpr.676.
Repligen inspiring advances in bioprocessing. Frequently asked questions—perfusion. Repligen inspiring advances in bioprocessing official web-site. 2017. https://www.repligen.com/products/upstream-solutions/xcell-atf-cell-retention-system/faq-perfusion/#steady. Accessed 1 June 2018.
Konstantinov KB, Cooney CL. White paper on continuous bioprocessing. May 20–21, 2014 continuous manufacturing symposium. J Pharm Sci. 2015;104(3):813–20. https://doi.org/10.1002/jps.24268.
Roque ACA, Lowe CR, Taipa MÂ. Antibodies and genetically engineered related molecules: production and purification. Biotechnol Prog. 2004;20(3):639–54.
Azevedo AM, Rosa PAJ, Ferreira IF, Aires-Barros MR. Chromatography-free recovery of biopharmaceuticals through aqueous two-phase processing. Trends Biotechnol. 2009;27(4):240–7. https://doi.org/10.1016/j.tibtech.2009.01.004.
Farid SS. Economic drivers and trade-offs in antibody purification processes. BioPharm International. 2009; 2009(7).
Karst DJ, Serra E, Villiger TK, Soos M, Morbidelli M. Characterization and comparison of ATF and TFF in stirred bioreactors for continuous mammalian cell culture processes. Biochem Eng J. 2016;110:17–26. https://doi.org/10.1016/j.bej.2016.02.003.
Espitia-Saloma E, Vazquez-Villegas P, Rito-Palomares M, Aguilar O. An integrated practical implementation of continuous aqueous two-phase systems for the recovery of human IgG: from the microdevice to a multistage bench-scale mixer-settler device. Biotechnol J. 2016;11(5):708–16. https://doi.org/10.1002/biot.201400565.
Angarita M, Muller-Spath T, Baur D, Lievrouw R, Lissens G, Morbidelli M. Twin-column CaptureSMB: a novel cyclic process for protein A affinity chromatography. J Chromatogr A. 2015;1389:85–95. https://doi.org/10.1016/j.chroma.2015.02.046.
Varadaraju H, Schneiderman S, Zhang L, Fong H, Menkhaus TJ. Process and economic evaluation for monoclonal antibody purification using a membrane-only process. Biotechnol Prog. 2011;27(5):1297–305. https://doi.org/10.1002/btpr.639.
Liu SS, Papageorgiou LG. Multi-objective optimisation for biopharmaceutical manufacturing under uncertainty. Comput Chem Eng. 2018;119:383–93. https://doi.org/10.1016/j.compchemeng.2018.09.015.
Popova D, Stonier A, Pain D, Titchener-Hooker NJ, Farid SS. Integrated economic and experimental framework for screening of primary recovery technologies for high cell density CHO cultures. Biotechnol J. 2016;11(7):899–909. https://doi.org/10.1002/biot.201500336.
Torres-Acosta MA, Pereira JFB, Freire MG, Aguilar-Yanez JM, Coutinho JAP, Titchener-Hooker NJ, et al. Economic evaluation of the primary recovery of tetracycline with traditional and novel aqueous two-phase systems. Sep Purif Technol. 2018;203:178–84. https://doi.org/10.1016/j.seppur.2018.04.041.
Lopes AG. Single-use in the biopharmaceutical industry: a review of current technology impact, challenges and limitations. Food Bioprod Process. 2015;93:98–114. https://doi.org/10.1016/j.fbp.2013.12.002.
Berthold Boedeker JM. Opportunities and limitations of continuous processing and use of disposables. Am Pharm Rev. 2017.
Shukla AA, Gottschalk U. Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol. 2013;31(3):147–54. https://doi.org/10.1016/j.tibtech.2012.10.004.
Langer ES, Rader RA. Single-use technologies in biopharmaceutical manufacturing: a 10-year review of trends and the future. Engineering in Life Sciences. 2014;14(3):238–43. https://doi.org/10.1002/elsc.201300090.
Marc Bisschops LF, Scott Fulton, Tom Ransohoff. Single-use, continuous-countercurrent, multicolumn chromatography. BioProcess International. 2009.
Michael LaBreck MP. An economic analysis of single—use tangential flow filtration for biopharmaceutical applications. BioProcess International. 2010;2010 Supplement(8).
Jacquemart R, Vandersluis M, Zhao MC, Sukhija K, Sidhu N, Stout J. A single-use strategy to enable manufacturing of affordable biologics. Comput Struct Biotec. 2016;14:309–18. https://doi.org/10.1016/j.csbj.2016.06.007.
Shirahata H, Hirao M, Sugiyama H. Decision-support method for the choice between single-use and multi-use technologies in sterile drug product manufacturing. J Pharm Innov. 2017;12(1):1–13. https://doi.org/10.1007/s12247-016-9264-7.
Magnus J, Temming M, Schwan P, Micovic J, Lobedam M, Sievers S, editors. A biomanufacturing facility based on continuous processing and single use technology2015.
Yang WC, Lu J, Kwiatkowski C, Yuan H, Kshirsagar R, Ryll T, et al. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality. Biotechnol Prog. 2014;30(3):616–25. https://doi.org/10.1002/btpr.1884.
Farid SS. Established bioprocesses for producing antibodies as a basis for future planning. In: Hu W-S, editor. Cell Culture Engineering. Berlin, Heidelberg: Springer Berlin Heidelberg; 2006. p. 1–42.
Rathore AS, Agarwal H, Sharma AK, Pathak M, Muthukumar S. Continuous processing for production of biopharmaceuticals. Prep Biochem Biotechnol. 2015;45(8):836–49. https://doi.org/10.1080/10826068.2014.985834.
St Amand MM, Hayes J, Radhakrishnan D, Fernandez J, Meyer B, Robinson AS, et al. Identifying a robust design space for glycosylation during monoclonal antibody production. Biotechnol Prog. 2016;32(5):1149–62. https://doi.org/10.1002/btpr.2316.
Radhakrishnan D, Robinson AS, Ogunnaike BA. Controlling the glycosylation profile in mAbs using time-dependent media supplementation. Antibodies. 2018;7(1):1. https://doi.org/10.3390/antib7010001.
Ogonah OW, Polizzi KM, Bracewell DG. Cell free protein synthesis: a viable option for stratified medicines manufacturing? Curr Opin Chem Eng. 2017;18:77–83. https://doi.org/10.1016/j.coche.2017.10.003.
Stech M, Kubick S. Cell-free synthesis meets antibody production: a review. Antibodies. 2015;4(1):12–33. https://doi.org/10.3390/antib4010012.
Martin RW, Majewska NI, Chen CX, Albanetti TE, Jimenez RBC, Schmelzer AE, et al. Development of a CHO-based cell-free platform for synthesis of active monoclonal antibodies. ACS Synth Biol. 2017;6(7):1370–9. https://doi.org/10.1021/acssynbio.7b00001.
Shirokov VA, Simonenko PN, Biryukov SV, Spirin AS. Continuous-flow and continuous-exchange cell-free translation systems and reactors. In: Spirin AS, editor. Cell-free translation systems. Berlin, Heidelberg: Springer Berlin Heidelberg; 2002. p. 91–107.
Stech M, Nikolaeva O, Thoring L, Stocklein WFM, Wustenhagen DA, Hust M, et al. Cell-free synthesis of functional antibodies using a coupled in vitro transcription-translation system based on CHO cell lysates. Sci Rep-Uk. 2017;7:12030. https://doi.org/10.1038/s41598-017-12364-w.
Dutta AK, Tran T, Napadensky B, Teella A, Brookhart G, Ropp PA, et al. Purification of monoclonal antibodies from clarified cell culture fluid using Protein A capture continuous countercurrent tangential chromatography. J Biotechnol. 2015;213:54–64. https://doi.org/10.1016/j.jbiotec.2015.02.026.
Dutta AK, Fedorenko D, Tan J, Costanzo JA, Kahn DS, Zydney AL, et al. Continuous countercurrent tangential chromatography for mixed mode post-capture operations in monoclonal antibody purification. J Chromatogr A. 2017;1511:37–44. https://doi.org/10.1016/j.chroma.2017.06.018.
Rosa PA, Azevedo AM, Sommerfeld S, Mutter M, Backer W, Aires-Barros MR. Continuous purification of antibodies from cell culture supernatant with aqueous two-phase systems: from concept to process. Biotechnol J. 2013;8(3):352–62. https://doi.org/10.1002/biot.201200031.
Rosa PAJ, Azevedo AM, Sommerfeld S, Bäcker W, Aires-Barros MR. Aqueous two-phase extraction as a platform in the biomanufacturing industry: economical and environmental sustainability. Biotechnol Adv. 2011;29(6):559–67. https://doi.org/10.1016/j.biotechadv.2011.03.006.
Rosa PAJ, Ferreira IF, Azevedo AM, Aires-Barros MR. Aqueous two-phase systems: a viable platform in the manufacturing of biopharmaceuticals. J Chromatogr A. 2010;1217(16):2296–305. https://doi.org/10.1016/j.chroma.2009.11.034.
Fisher AC, Kamga MH, Agarabi C, Brorson K, Lee SL, Yoon S. The current scientific and regulatory landscape in advancing integrated continuous biopharmaceutical manufacturing. Trends Biotechnol. 2018. https://doi.org/10.1016/j.tibtech.2018.08.008.
Fisher AC, Lee SL, Harris DP, Buhse L, Kozlowski S, Yu L, et al. Advancing pharmaceutical quality: an overview of science and research in the U.S. FDA’s Office of Pharmaceutical Quality. Int J Pharm. 2016;515(1–2):390–402. https://doi.org/10.1016/j.ijpharm.2016.10.038.
Raftery JP, DeSessa MR, Karim MN. Economic improvement of continuous pharmaceutical production via the optimal control of a multifeed bioreactor. Biotechnol Prog. 2017;33(4):902–12. https://doi.org/10.1002/btpr.2433.
This work was supported by Eli Lilly and company.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yang, O., Qadan, M. & Ierapetritou, M. Economic Analysis of Batch and Continuous Biopharmaceutical Antibody Production: a Review. J Pharm Innov 15, 182–200 (2020). https://doi.org/10.1007/s12247-018-09370-4
- Economic analysis
- Batch and continuous biopharmaceutical manufacturing
- Antibody production
- Simulation software